Prime Medicine, Inc./$PRME
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Ticker
$PRME
Sector
Primary listing
Employees
214
Headquarters
Website
PRME Metrics
BasicAdvanced
$960M
-
-$1.57
2.41
-
Price and volume
Market cap
$960M
Beta
2.41
52-week high
$6.94
52-week low
$1.11
Average daily volume
3.8M
Financial strength
Current ratio
3.556
Quick ratio
2.987
Long term debt to equity
184.814
Total debt to equity
196.74
Profitability
EBITDA (TTM)
-197.384
Gross margin (TTM)
-3,012.62%
Net profit margin (TTM)
-4,016.83%
Operating margin (TTM)
-4,116.57%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-47.39%
Return on equity (TTM)
-154.81%
Valuation
Price to revenue (TTM)
145.302
Price to book
12.23
Price to tangible book (TTM)
12.23
Price to free cash flow (TTM)
-6.737
Free cash flow yield (TTM)
-14.84%
Free cash flow per share (TTM)
-0.843
Growth
Revenue change (TTM)
739.42%
Earnings per share change (TTM)
-26.34%
3-year earnings per share growth (CAGR)
-43.82%
Bulls say / Bears say
Prime Medicine reported positive proof-of-concept results from two Phase 1/2 CGD patients, showing rapid engraftment and restoration of NADPH oxidase activity well above the threshold needed for clinical benefit (Prime Medicine Q2 Release).
The company completed a $144.2 million follow-on public offering in August 2025 and secured up to $24 million in additional funding from the Cystic Fibrosis Foundation, extending its pro-forma cash runway through 2027 (Prime Medicine Q2 Release; Cystic Fibrosis Foundation).
A strategic restructuring reoriented internal efforts toward high-value liver programs for Wilson’s Disease and Alpha-1 Antitrypsin Deficiency, with IND filings expected in 1H 2026 and mid-2026 and initial clinical data due in 2027, outlining clear near-term milestones (Prime Medicine Restructuring).
Cash, cash equivalents, and investments dropped to $115.4 million as of June 30, 2025, from $204.5 million at December 31, 2024, highlighting a high cash burn rate and ongoing dependence on dilutive financing (Prime Medicine Q2 Release).
Prime Medicine’s in-house funded in vivo programs for Wilson’s Disease and AATD will not deliver initial clinical data until 2027, which creates a multi-year valuation gap and adds near-term uncertainty for investors (Prime Medicine Restructuring).
Deprioritizing the CGD program despite positive Phase 1/2 data, along with binding arbitration with Beam Therapeutics over AATD rights, points to resource constraints and potential legal distractions that could slow pipeline progress (Prime Medicine Restructuring).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
PRME News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prime Medicine, Inc. stock?
Prime Medicine, Inc. (PRME) has a market cap of $960M as of October 12, 2025.
What is the P/E ratio for Prime Medicine, Inc. stock?
The price to earnings (P/E) ratio for Prime Medicine, Inc. (PRME) stock is 0 as of October 12, 2025.
Does Prime Medicine, Inc. stock pay dividends?
No, Prime Medicine, Inc. (PRME) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Prime Medicine, Inc. dividend payment date?
Prime Medicine, Inc. (PRME) stock does not pay dividends to its shareholders.
What is the beta indicator for Prime Medicine, Inc.?
Prime Medicine, Inc. (PRME) has a beta rating of 2.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.